Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL The American Journal of Managed Care® (AJMC®)Allogeneic CD19 CAR NK-Cell Therapy Induces Durable Disease Control in Waldenstrom Lymphoma OncLiveImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results Yahoo FinanceImmunityBio touts 15-month complete response in CAR-NK trial Fierce BiotechImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma Business Wire